Skip to main
COCH
COCH logo

COCH Stock Forecast & Price Target

COCH Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Envoy Medical's stock outlook is bolstered by its attractive current valuation, highlighting a significant upside potential based on a net present value (NPV) analysis. The company stands to benefit from the substantial expansion opportunities within the international hearing device market, which accounts for approximately 50% of total industry sales. Additionally, recent FDA approval of the Acclaim CI for clinical testing signifies an important milestone that could lead to further advancements in Envoy Medical's product offerings and revenue generation.

Bears say

Envoy Medical Inc reported a net loss of $6.2 million, translating to an earnings per share (EPS) of $(0.29), which slightly outperformed internal estimates and the consensus forecast. Despite acknowledging growth prospects, the company's financial outlook is marred by significant risks, including balance sheet and liquidity issues, the potential failure of products to achieve required safety and efficacy in clinical trials, and challenges related to regulatory approvals and commercialization. Additionally, competition and changing macroeconomic conditions further complicate the market landscape, contributing to an overall negative sentiment regarding the company's financial stability and stock performance.

COCH has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Envoy Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Envoy Medical Inc (COCH) Forecast

Analysts have given COCH a Strong Buy based on their latest research and market trends.

According to 1 analysts, COCH has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Envoy Medical Inc (COCH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.